| Today's Top Story |  |  | | - J&J, Genmab ink $1.1B deal over cancer drug
Johnson & Johnson's Janssen Biotech will pay Danish biotech firm Genmab $55 million for global license rights to cancer agent daratumumab, and Johnson & Johnson Development Corp. will invest $80 million in new shares of Genmab, the companies announced. Janssen will pay all future development and commercialization costs for daratumumab, and Genmab may see up to $1 billion in milestone payments. Bloomberg Businessweek/The Associated Press (8/30), Reuters (8/30)        |  |  | | How to turn money you already spend into points you can use:
The Business Gold Rewards Card from American Express OPEN, designed to earn Membership Rewards® points faster: 3X on airfare. 2X on advertising, gas & shipping. 1X on everything else. Use points to pay for travel, Amazon.com purchases, Facebook ads, and more.
LEARN MORE & APPLY | |  |  |  |
  | Health Care & Policy | | | | - Teva's white blood cell booster receives FDA approval
The FDA has approved Teva's tbo-filgrastim, which boosts white blood cells, in some cancer patients undergoing chemotherapy. The drug is similar to but not substitutable with Amgen's Neupogen, whose patent expires next year, and Teva previously agreed not to market tbo-filgrastim until November 2013. Teva's tbo-filgrastim is already available in Europe. Reuters (8/29) - FDA permits Proacta to test cancer drug
The FDA approved Proacta's investigational new-drug application for its experimental cancer drug PR610, a hypoxia-activated irreversible multi-kinase inhibitor. The firm will initiate a clinical study focusing on nonsmall-cell lung cancer cases that don't respond to reversible tyrosine kinase inhibitors. Pharmaceutical Business Review Online (8/30) - Ziopharm cautiously courts partners for next-gen oncology drugs
Backed by Fidelity, Ziopharm executives are awaiting late-stage trial data on soft-tissue sarcoma chemotherapy drug palifosfamide -- an alkylating agent that interacts with cancer stem cells and might work in resistant tumors. Ziopharm's other projects include Ad-IL-12, which delivers an interleukin 12-producing gene into patients' cells that is switched on or off with a pill. Instead of seeking big institutional investors for this and other synthetic biology projects, Ziopharm is backing the research itself while selectively pursuing partners, CEO Jonathan Lewis says. Xconomy/New York (8/29) - Spinifex drug works against postherpetic neuralgia in study
A midstage study found that Spinifex Pharmaceuticals' postherpetic neuralgia drug candidate EMA401 reduced the mean daily pain score during the final week of 28 days of treatment. "We look forward to advancing EMA401 further in PHN and other neuropathic-pain indications, including cancer chemotherapy-induced neuropathic pain and painful diabetic neuropathy," CEO Tom McCarthy said. Pharmaceutical Business Review Online (8/29) | Company & Financial News | | | | - Sunovion will buy Elevation in deal worth as much as $430M
Sunovion Pharmaceuticals agreed to pay $100 million upfront to acquire Elevation Pharmaceuticals, a biopharmaceutical firm developing aerosol treatments for respiratory illnesses. The deal gives Sunovion rights to EP-101, an inhaled solution under midstage development for chronic obstructive pulmonary disease. Aside from the upfront payment, Elevation is entitled to as much as $300 million in milestone fees for EP-101, plus as much as $30 million conditional on successful development of additional programs. Mass High Tech (Boston) (8/30), Xconomy/San Diego (8/30)
| Food & Agriculture | | | | - Australia, India collaborate to develop iron-rich bananas
The Queensland University of Technology in Australia and India's Department of Biotechnology agreed to jointly develop strains of iron-rich bananas to help prevent iron-deficiency anemia, a leading cause of maternal death during childbirth. Under terms of the deal, DBT's Biotechnology Industry Research Assistance Council will provide $1.24 million to Australian researchers and $1.45 million to their Indian counterparts. "This is a significant step forward in addressing a major health issue in India's nutrition deficient population," said BIRAC Managing Director Dr. Renu Swarup. Yahoo!/Asian News International (8/29) | Industrial & Environmental | | | | | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| Editor's Note | | | | - SmartBrief will not publish Monday
In observance of Labor Day in the U.S., SmartBrief will not be published Monday. Publication will resume Tuesday. | SmartQuote | | | |  | I think, at a child's birth, if a mother could ask a fairy godmother to endow it with the most useful gift, that gift would be curiosity."
--Eleanor Roosevelt,
U.S. first lady  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, August 30, 2012
- Wednesday, August 29, 2012
- Tuesday, August 28, 2012
- Monday, August 27, 2012
- Friday, August 24, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment